rivaroxaban and Hypertension--Portal

rivaroxaban has been researched along with Hypertension--Portal* in 1 studies

Other Studies

1 other study(ies) available for rivaroxaban and Hypertension--Portal

Article	Year
The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6 RVXB decreases PP in two rat models of cirrhosis. This effect is mostly associated with decreased IHVR, enhanced NO bioavailability, HSC deactivation, and reduced intrahepatic microthrombosis. Our findings suggest that RVXB deserves further evaluation as a potential treatment for cirrhotic PH. (Hepatology 2017;65:2031-2044). Topics: Administration, Oral; Animals; Anticoagulants; Cells, Cultured; Disease Models, Animal; Endothelium, Vascular; Hepatic Stellate Cells; Hypertension, Portal; Liver Cirrhosis; Male; Oxidative Stress; Portal Pressure; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reference Values; Rivaroxaban; Statistics, Nonparametric; Treatment Outcome; Vascular Resistance	2017

Article

Year

The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.

Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6

RVXB decreases PP in two rat models of cirrhosis. This effect is mostly associated with decreased IHVR, enhanced NO bioavailability, HSC deactivation, and reduced intrahepatic microthrombosis. Our findings suggest that RVXB deserves further evaluation as a potential treatment for cirrhotic PH. (Hepatology 2017;65:2031-2044).

Topics: Administration, Oral; Animals; Anticoagulants; Cells, Cultured; Disease Models, Animal; Endothelium, Vascular; Hepatic Stellate Cells; Hypertension, Portal; Liver Cirrhosis; Male; Oxidative Stress; Portal Pressure; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reference Values; Rivaroxaban; Statistics, Nonparametric; Treatment Outcome; Vascular Resistance

2017